Skip to product information
1 of 1

GeneBio Systems

DPP4/CD26 Polyclonal Antibody

DPP4/CD26 Polyclonal Antibody

SKU:AN006840L

Regular price $154.00 USD
Regular price Sale price $154.00 USD
Sale Sold out
Shipping calculated at checkout.

Size::25μL

Storage:Store at -20℃ Valid for 12 months. Avoid freeze / thaw cycles.

Shipping:The product is shipped with ice pack, upon receipt, store it immediately at the temperature recommended.

Exp date:12 months

Category ID_II:Primary Antibodies

Category ID_III:Polyclonal Antibodies

Abbreviation:DPP4

Target Synonym:DPP;Adenosine Deaminase Complexing Protein;ADCP;ADABP;ADCP2;Adenosine Deaminase Complexing Protein 2;DPPIV;TP103;Cd26;Dpp4;Dipeptidyl peptidase IV (DPP IV); THAM

Research Areas:

Conjugation:Unconjugated

Host:Rabbit

Species reactivity:Mouse;Rat

Application:WB

Isotype:IgG

Clonality:Polyclonal

Clone NO.:

UNIProt ID:P28843

Accession:

Background:Dipeptidyl peptidase-4 (DPP4) or adenosine deaminase complexing protein 2 (ADCP 2) or T-cell activation antigen CD26 is a serine exopeptidase belonging to the S9B protein family that cleaves X-proline dipeptides from the N-terminus of polypeptides, such as chemokines, neuropeptides, and peptide hormones. The enzyme is a type II transmembrane glycoprotein, expressed on the surface of many cell types. It is also present in serum and other body fluids in a truncated form (sCD26/DPPIV). The soluble CD26 (sCD26) as a tumour marker for the detection of colorectal cancer (CRC) and advanced adenomas. As both a regulatory enzyme and a signalling factor, DPP4 has been evaluated and described in many studies. DPP4 inhibition results in increased blood concentration of the incretin hormones glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP). This causes an increase in glucose-dependent stimulation, resulting in a lowering of blood glucose levels. Recent studies have shown that DPP4 inhibitors can induce a significant reduction in glycosylated haemoglobin (HbA(1c)) levels, either as monotherapy or as a combination with other antidiabetic agents. Research has also demonstrated that DPP4 inhibitors portray a very low risk of hypoglycaemia development, and are a new pharmacological class of drugs for treating Type 2 diabetes.

Concentration:1 mg/mL

Immunogen:Recombinant Mouse DPP4/CD26 protein expressed by Mammalian

Buffer:PBS with 0.05% proclin 300, 1% protective protein and 50% glycerol,pH7.4

Purification method:Antigen Affinity Purification

Dilution:WB 1:1000-1:2000

Calculated MW:87 kDa

ObservedMW:110 kDa

View full details